VEGFA and neoplasm: Thus, VEGF-targeted drugs (anti-angiogenic therapy) are a pioneering approach to the target tumour microenvironment and creates intratumor hypoxia, which leads to the selection of more invasive and resistant anti-angiogenic therapy cancer cells.